Related Experiment Videos
[Clinical evaluation of cefoperazone in children (author's transl)]
Insights
Cefoperazone (CPZ) demonstrates effectiveness in treating pediatric bacterial infections, with good serum concentration profiles and high efficacy rates. Adverse reactions were minimal, indicating a favorable safety profile for children.
Area of Science:
- Pediatric Infectious Diseases
- Pharmacokinetics and Pharmacodynamics
- Antibiotic Therapy
Background:
- Evaluation of cefoperazone (CPZ) in pediatric patients.
- Assessment of drug pharmacokinetics and clinical efficacy.
- Investigation of safety and adverse reactions.
Observation:
- Serum concentrations of CPZ varied based on administration route and patient condition.
- Pharmacokinetic parameters, including T 1/2, were analyzed in different clinical scenarios.
- Clinical efficacy was assessed in patients with pyelonephritis, pneumonia, and postoperative infections.
Findings:
- CPZ showed high efficacy rates (excellent in 3, good in 2) with causative organisms eradicated in all treated patients.
- Pharmacokinetic studies revealed varying serum concentrations and T 1/2 values depending on administration.
- No significant adverse reactions were observed, except for mild eosinophilia in two cases.
Implications:
- Cefoperazone (CPZ) is an effective antibiotic for treating bacterial infections in children.
- The drug exhibits a favorable pharmacokinetic profile and a good safety margin in pediatric populations.
- Further clinical studies may support the expanded use of CPZ in pediatric infectious disease management.
Abstract:
Clinical evaluation was made on cefoperazone (CPZ) and the following conclusions were obtained. (1) Serum concentrations of the drug after a one-shot intravenous injection of 22.2 mg/kg were 77 mcg/ml (30 minutes), 50 mcg/ml (1 hour) and 8.9 mcg/ml (4 hours) and T 1/2 of serum concentration was 68.5 minutes. A 35-day-old female with obstructive jaundice associated with choledochal cyst was given by a 30-minute drip infusion of 26.8 mg/kg of the drug. Serum concentration was 90 mcg/ml at the end of infusion, slowly declined thereafter, and was 47.5 mcg/ml at 6 hours. Its T 1/2 was 395 minutes. A patient with pyelonephritis complicated with right hydronephrosis was similarly treated with 24.4 mg/kg. T 1/2 of serum concentration was not prolonged, i.e., 82.1 minutes, but urinary recovery rate up to 6 hours was decreased to 15.9%. (2) Five patients, including three with pyelonephritis (causative organism: K. pneumoniae 2 and P. aeruginosa 1) and each one patient with pneumonia (unknown) and with postoperative infection (S. faecalis), respectively, were treated with 66.7 approximately 96.8 mg/kg/day of CPZ in 3 divided doses for 5 approximately 12 days either by one-shot intravenous or by 30 approximately 60-minute drip infusion. An overall efficacy rate was excellent in 3 and good in 2, and there was no failure. Causative organisms disappeared in all cases. (3) Although one patient was excluded from the study because the diagnosis was supposed to be viral pneumonia, all six patients who were given CPZ did not exhibit any adverse reactions except for mild eosinophilia in two instances. (4) The foregoing results as well as the review of the literature clearly indicate the effectiveness of CPZ in the treatment of bacterial infections in children.